ProShare Advisors
KBIO

ProShare Advisors’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

ProShare Advisors’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,506
Closed -$33K – 2831
2014
Q1 		$33K Buy
+1,506
New +$43.6K ﹤0.01% 2723

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ProShare Advisors's KBIO Position: Q2 2014 in Review

ProShare Advisors sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2014, closing a stake of 1,506 shares — an estimated $33K sold.

ProShare Advisors first reported a position in KBIO in Q1 2014 and held it in 1 quarter. The position peaked at $33K in Q1 2014. 43 funds tracked by Wall St. Rank hold KBIO as of Q2 2014.

  • ProShare Advisors reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2014 after selling out during the quarter.
  • ProShare Advisors sold 1,506 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2014, an estimated $33K.
  • ProShare Advisors first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q1 2014 and held it in 1 quarter.
  • ProShare Advisors's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $33K in Q1 2014.
  • 43 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2014.

Based on ProShare Advisors's 13F filing for Q2 2014, filed 8 Aug 2014.